MMW Fortschr Med. 2000 Mar 13;142 Suppl 1:34-9. Unique Identifier : AIDSLINE MED/20321529
Manegold C; Bernhard-Nocht-Institut fur Tropenmedizin, Klinische Abteilung,; Hamburg. manegold@bni.uni-hamburg.de
Abstract: While the effectiveness of conventional antiviral treatment is well proven, its limitations are becoming more and more evident. New approaches are resulting from the "decoding" of the pathogenesis of HIV infection. Thus, for example, experimental studies are looking at drug-induced blockade of the co-receptors necessary for the infection of the target cells. Treatment can be applied at all stages of viral replication. So far, reverse transcriptase and protease inhibitors have been employed. Other strategies are aimed at immunostimulation (e.g. with interleukin 2) and immunosuppression (cortisone, hydroxyurea). The development of therapeutic vaccines is difficult, but prophylactic vaccines hold out greater promise; field trials are underway.
Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .